Herein we suggest that retinal endovascular delivery of anti-VEGF is feasible based on prior nonrandomised clinical trials using systemic anti-VEGF (bevacizumab), which showed efficacy in AMD and non-AMD related choroidal neovascularisation but can be associated with hypertension [36, 43]. The gene discussed is VEGFA; the disease is age-related macular degeneration.